Nutrition-Related Liver Disease Treatments Advance In An Uncertain New World
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Detection and treatments of parenteral nutrition-associated liver disease, a serious complication of the life-saving therapy for patients who can’t absorb enteral nutrients, have advanced to the point where trial design has become more challenging.
You may also be interested in...
Gastroenterology Endpoints To Get Four-Day Series Of FDA Workshops
One day each will be devoted to eosinophilic esophagitis, pediatric and adult inflammatory bowel disease, and parenteral nutrition-associated liver disease, Sept. 19, 20, 21 and 24, in that order.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.